# Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

> **NCT03033745** · PHASE4 · COMPLETED · sponsor: **CSL Behring** · enrollment: 49 (actual)

## Conditions studied

- Primary Immunodeficiency

## Interventions

- **DRUG:** IgPro20

## Key facts

- **NCT ID:** NCT03033745
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-01
- **Primary completion:** 2018-12-14
- **Final completion:** 2018-12-14
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03033745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03033745, "Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03033745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*